Is axitinib/axitinib on the market?

Axitinib/Axitinib is a second-generation tyrosine kinase inhibitor that mainly works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). This mechanism allows axitinib to effectively block angiogenesis, thereby inhibiting tumor growth and metastasis. Studies have shown that axitinib is 50 to 450 times more effective than first-generation VEGFR inhibitors, so it has shown good therapeutic effects in clinical applications.

The chemical structure of axitinib is an indazole derivative, which is usually marketed under the trade nameInlyta and is available in oral dosage forms. Since 2012, the drug has been approved in several countries and regions for the treatment of renal cell carcinoma. Specifically, axitinib was first approved by the US Food and Drug Administration (FDA) in January 2012, and subsequently by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in September of the same year. In addition, axitinib was approved by the Australian Therapeutic Goods Administration (TGA) in July 2012.

In China, axitinib was approved for marketing by the State Food and Drug Administration in April 2015 with the trade name "Inlida". The launch of this drug provides a new treatment option for patients with renal cell carcinoma, especially for those whose disease has progressed despite first-line treatment. Clinical studies have shown that axitinib has a positive effect in delaying disease progression and improving patients' quality of life.

Overall, the launch of axitinib not only enriches the treatment options for renal cell carcinoma, but also brings new hope to patients. As the drug is further studied, its potential for use in other types of cancer may be explored in the future, providing treatment options for a wider patient population.

Reference materials:https://en.wikipedia.org/wiki/Axitinib